Back to top
more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$76.28 USD

76.28
6,661,532

-0.79 (-1.03%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $76.29 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (101 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks News

Zacks Equity Research

Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up

Sanofi (SNY) posts first-quarter 2024 results and maintains the earnings growth guidance for the year.

Zacks Equity Research

Q1 GDP Increased Lower Than Expectations

Q1 GDP Increased Lower Than Expectations

Mark Vickery headshot

Is "Bad News" Still "Good News" for the Market?

If we're looking for the Fed to lower interest rates, don't we need softer economic data like what we saw today?

Zacks Equity Research

Astrazeneca (AZN) Reports Q1 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Astrazeneca (AZN) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect

Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.

Zacks Equity Research

Insights Into Astrazeneca (AZN) Q1: Wall Street Projections for Key Metrics

Beyond analysts' top -and-bottom-line estimates for Astrazeneca (AZN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.

Zacks Equity Research

Astrazeneca (AZN) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.

Zacks Equity Research

AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids

The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News

J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors.

Zacks Equity Research

Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know

Astrazeneca (AZN) closed the most recent trading day at $69.45, moving +1.97% from the previous trading session.

Zacks Equity Research

Atossa (ATOS) Reports Positive Results From EVANGELINE Study

Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.

Zacks Equity Research

Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study

Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies.

Zacks Equity Research

Pfizer's (PFE) RSV Vaccine Study in Adults Under 60 Meets Goal

Pfizer's (PFE) RSV vaccine, Abrysvo, generates an immune response in a phase III study evaluating it in higher-risk adults aged 18 to 59, non-inferior to that in older adults.

Zacks Equity Research

Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised)

Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.

Zacks Equity Research

AstraZeneca's (AZN) Enhertu Gets FDA Nod for Solid Tumors

FDA approves AstraZeneca (AZN) and partner Daiichi Sankyo's Enhertu for HER2-expressing metastatic cancers based on data from three phase II studies.

Zacks Equity Research

Astrazeneca (AZN) Advances But Underperforms Market: Key Facts

Astrazeneca (AZN) closed the most recent trading day at $67.45, moving +0.16% from the previous trading session.

Zacks Equity Research

AstraZeneca's (AZN) Imfinzi Improves Survival in SCLC Study

AstraZeneca's (AZN) Imfinzi improves overall survival and progression-free survival for patients with limited-stage small cell lung cancer in the phase III ADRIATIC study.

Kinjel Shah headshot

Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III

FDA approves AstraZeneca's (AZN) Voydeya (danicopan) in the United States as add on therapy to its other C5 inhibitors. Merck (MRK) begins a phase III study on its oral KRAS G12C inhibitor candidate.

Zacks Equity Research

Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up

Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.

Zacks Equity Research

The Zacks Analyst Blog Highlights Berkshire Hathaway, Procter & Gamble, Adobe, Advanced Micro Devices and AstraZeneca

Berkshire Hathaway, Procter & Gamble, Adobe, Advanced Micro Devices and AstraZeneca are included in this Analyst Blog.

Zacks Equity Research

Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug

Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.

Sheraz Mian headshot

Top Research Reports for Berkshire Hathaway, Procter & Gamble & Adobe

Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), The Procter & Gamble Company (PG) and Adobe Inc. (ADBE).

Zacks Equity Research

Are You Looking for a High-Growth Dividend Stock?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.

Zacks Equity Research

AstraZeneca (AZN) Dato-DXd Breast Cancer BLA Gets FDA Acceptance

AstraZeneca's (AZN) BLA is seeking approval of Dato-DXd for previously treated metastatic HR-positive, HER2-negative breast cancer.

Zacks Equity Research

AstraZeneca's (AZN) Rare Blood Disorder Drug Gets FDA Nod

FDA approves AstraZeneca's (AZN) Voydeya as an add-on to therapy to Ultomiris or Soliris for treating extravascular hemolysis in adult patients with paroxysmal nocturnal hemoglobinuria.